Back to search results

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib

Abroad (travel likely)RecruitingPHASE2

Conditions

Endometrioid Cancer · Mucinous Ovarian Cancer · High Grade Serous Ovarian Cancer · Cervical Cancer · Solid Tumor

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • AdventHealth, Orlando, Florida, United States

    Contact: Study coordinator (Robert Holloway, MD) · Robert.Holloway.MD@AdventHealth.com · 407-303-2422
    Contact: Principal Investigator (Robert Holloway, MD)

  • Louisiana State University Medical Center New Orleans, New Orleans, Louisiana, United States

    Contact: Study coordinator (Tara Castellano, MD) · tcaste@lshuhsc.edu · 504-568-4850
    Contact: Principal Investigator (Tara Castellano, MD)

  • University of New Mexico Comprehensive Cancer Center, Albuquerque, New Mexico, United States

    Contact: Study coordinator (Carolyn Muller, MD) · cmuller@salud.unm.edu · 505-925-0460
    Contact: Principal Investigator (Carolyn C Muller, MD)

  • Stephenson Cancer Center, Oklahoma City, Oklahoma, United States

    Contact: Study coordinator (SCC IIT Office) · SCC-IIT-Office@ouhsc.edu · 405-271-8777
Study leads

  • Christina Washington, MD

    Principal Investigator

    OU Health Stephenson Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)